title: Selective expression of the receptor tyrosine kinase, HTK, on human erythroid progenitor cells.
abstract: HTK is a receptor tyrosine kinase of the Eph family. To characterize the involvement of HTK in hematopoiesis, we generated monoclonal antibodies against HTK and investigated its expression on human bone marrow cells. About 5% of the bone marrow cells were HTK+, which were also c-Kit+, CD34(low), and glycophorin A(-/low). Assays of progenitors showed that HTK+ c-Kit+ cells consisted exclusively of erythroid progenitors, whereas HTK- c-Kit+ cells contained progenitors of granulocytes and macrophages as well as those of erythroid cells. Most of the HTK+ erythroid progenitors were stem cell factor-dependent for proliferation, indicating that they represent mainly erythroid burst-forming units (BFU-E). During the erythroid differentiation of cultured peripheral CD34+ cells, HTK expression was upregulated on immature erythroid cells that corresponded to BFU-E and erythroid colony-forming units and downregulated on erythroblasts with high levels of glycophorin expression. These findings suggest that HTK is selectively expressed on the restricted stage of erythroid progenitors, particularly BFU-E, and that HTK is the first marker antigen that allows the purification of erythroid progenitors. Furthermore, HTKL, the ligand for HTK, was expressed in the bone marrow stromal cells. Our findings provide a novel regulatory system of erythropoiesis mediated by the HTKL-HTK signaling pathway.
authors.affiliation: Department of Cell Differentiation, Kumamoto University School of Medicine, Kumamoto City, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Inada
authors.forename: A
authors.initials: A
authors.lastname: Iwama
authors.forename: S
authors.initials: S
authors.lastname: Sakano
authors.forename: M
authors.initials: M
authors.lastname: Ohno
authors.forename: K
authors.initials: K
authors.lastname: Sawada
authors.forename: T
authors.initials: T
authors.lastname: Suda
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology; D015415:Biomarkers; D001773:Blood Cells / Q000201:enzymology; D001853:Bone Marrow / Q000201:enzymology; D001854:Bone Marrow Cells; D002478:Cells, Cultured; D004790:Enzyme Induction; D036388:Ephrin-B2; D015672:Erythroid Precursor Cells / Q000145:classification / Q000201:enzymology*; D004920:Erythropoiesis / Q000235:genetics; D006801:Humans; D007947:Leukemia, Megakaryoblastic, Acute / Q000201:enzymology / Q000473:pathology; D008565:Membrane Proteins / Q000502:physiology; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D020794:Receptor Protein-Tyrosine Kinases / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D036224:Receptor, EphB4; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D015415:Biomarkers; D036388:Ephrin-B2; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D020794:Receptor Protein-Tyrosine Kinases; D036224:Receptor, EphB4